Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
UTHR
#562
United Therapeutics Corporation - Common Stock
515.1
6
USD
+0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.94%
Monthly Change
-0.22%
6 month change
+1.10%
Year Change
+22.70%
Previous Close
510.3
8
Open
515.8
9
Low
514.4
9
High
516.6
1
Volume
92
Markets
US Stock Market
Healthcare
Biotechnology
UTHR
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Q1, 26
Q2, 26
Current
Key stats
Total common shares outstanding
45.11 M
45.23 M
43.06 M
43.83 M
42.45 M
42.89 M
42.89 M
Valuation ratios
Enterprise value
12.01 B
11.4 B
16.71 B
19.8 B
23.89 B
21.44 B
20.32 B
Price to earnings ratio
12.28
11.2
15.86
17.49
21.92
19.41
18.48
Price to sales ratio
5
4.53
6.49
7.33
8.92
8.08
7.69
Price to cash flow ratio
10.55
10.17
13.03
14.95
18.03
15.15
14.42
Price to book ratio
0.59
0.53
0.75
3.29
1.06
0.98
0.93
Enterprise value to EBITDA ratio
8.11
7.46
10.6
12.55
15.68
14.35
13.6
Profitability ratios
Return on assets %
0.04
0.04
0.05
0.05
0.04
0.05
0.05
Return on equity %
0.05
0.04
0.05
0.05
0.05
0.05
0.05
Return on invested capital %
28.97
25.04
29.34
27.74
26.99
29.64
29.64
Gross margin %
88.36
89.03
87.38
86.91
82.93
87.3
87.3
Operating margin %
48.19
45.64
48.59
45.14
41.69
42.23
42.23
EBITDA margin %
50.68
48.28
51.33
48.03
44.58
45.32
45.32
Net margin %
40.56
38.76
42.36
46.1
35.18
42.51
42.51
Liquidity ratios
Quick ratio
5.23
6.94
6.07
6.28
4.5
5.41
5.41
Current ratio
5.46
7.26
6.4
6.6
4.79
5.73
5.73
Inventory turnover
0.57
0.52
0.57
0.58
0.74
0.53
0.53
Asset turnover
0.11
0.1
0.11
0.1
0.11
0.11
0.11
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
0
0
0
—
—
—
Long term debt to total equity ratio
0.03
0
0
0
—
—
—
Per share metrics
Operating cash flow per share
9.49
3.97
11.88
7.23
9.82
6.85
35.77
EBIT per share
7.88
7.55
8.21
7.45
6.9
7.22
29.79
EBITDA per share
8.28
7.98
8.68
7.92
7.38
7.75
31.73
Total debt per share
—
—
—
—
—
—
—
Cash per share
68.72
63.42
58.94
63.62
47.01
59.85
59.85
Net current asset value per share
81.07
79.23
73.87
77.3
60.85
76.06
76.06
Tangible book value per share
137.77
146.21
136.86
145.71
122.58
137.25
137.25
Working capital per share
66.22
68.32
62.32
65.59
48.15
62.79
62.79
Book value per share
140.07
148.52
139.33
148.15
125.02
139.74
139.74
News
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
Will LQDA's Differentiated PAH Approach Drive Growth?
Tracking Renaissance Technologies (RenTec) 13F Portfolio – Q2 2026 Update
Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark